We welcome Northpond, Deerfield, and Casdin and are thrilled to have them join our existing investors in our shared goal of improving patient lives and outcomes. Neurodegenerative diseases represent a new and important frontier for innovation in the quest to address significant unmet needs and transform care.

“Northpond is excited to lead this investment as we believe Octave’s solution will transform the way neurodegenerative diseases will be managed by providing expanded insights into a patient’s specific disease stage, severity and progression while accessing care protocols and evidence-based insights to improve patient outcomes and quality of life.” -Michael Rubin, MD, PhD, Founder and CEO of Northpond Ventures.

“The key to improved performance is to lower MS disease activity, avoid relapses, slow progression and optimize the drugs now used. As the country’s first true population health precision medicine company, Octave can make a huge impact by providing physicians with the tools, pathways and protocols needed to improve performance. Moreover, programs to improve care coordination, optimize physician networks and deliver higher value case management can provide a major impact at the population level.” -Julian Harris, MD, Partner of Deerfield.

“The introduction of a novel, next-generation objective measurement and management system that will help patients and physicians understand disease trajectory and help to guide therapy decisions is the key to truly personalizing care management for a patient population looking for better answers. From the beginning, we have remained true to our goal of creating a new care model to improve health outcomes and deliver value throughout the entire MS ecosystem.” -Brook Byers, Chairman and founding investor in Octave Bioscience.